CME Group Inc. (CME)
Down But Not Out: Why CME Group Remains One Of My Favorite Dividend Stocks
CME Group Inc.'s stock has recently underperformed, falling 8.5% despite its long-term success and status as a key player in the financial sector. The company boasts a wide-moat business with strong financials, including record revenue growth and high margins, driven by diverse futures and options contracts. Despite challenges like increased competition and low volatility, CME Group's solid earnings, attractive dividends, and current undervaluation make it a compelling buy.
CME Group (CME) Q2 Earnings Top on Record Trading Volume
CME Group (CME) Q2 results reflect benefits of record trading volumes.
CME Group Inc. (CME) Q2 2024 Earnings Call Transcript
CME Group Inc. (NASDAQ:CME ) Q2 2024 Earnings Conference Call July 24, 2024 8:30 PM ET Company Participants Adam Minick - Head of IR Terrence Duffy - Chairman, CEO Lynne Fitzpatrick - CFO Sunil Cutinho - Chief Information Officer Derek Sammann - Senior Managing Director, Global Head of Commodities Kendal Vroman - Chief Transformation Officer Tim McCourt - Senior Managing Director, Global Head of Financial Julie Winkler - CCO Conference Call Participants Patrick Moley - Piper Sandler Benjamin Budish - Barclays Simon Clinch - Redburn Atlantic Dan Fannon - Jefferies Owen Lau - Oppenheimer Chris Allen - Citi Craig Siegenthaler - Bank of America Kyle Voigt - KBW Michael Cyprys - Morgan Stanley Alex Blostein - Goldman Sachs Brian Bedell - Deutsche Bank Ken Worthington - JP Morgan Eli Abboud - Bank of America Operator Welcome to the CME Group Second Quarter 2024 Earnings Call. At this time I would like to inform all participants that your lines have been placed on a listen-only mode until the question-and-answer session of today's conference.
Here's What Key Metrics Tell Us About CME (CME) Q2 Earnings
While the top- and bottom-line numbers for CME (CME) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CME Group (CME) Tops Q2 Earnings and Revenue Estimates
CME Group (CME) came out with quarterly earnings of $2.56 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.30 per share a year ago.
Is a Beat in the Cards for CME Group (CME) in Q2 Earnings?
CME Group's (CME) second-quarter 2024 results are likely to reflect a diverse product portfolio, increased volatility, as well as a strong market position.
Here's Why You Should Retain CME Group (CME) Stock Right Now
CME Group (CME) stands to benefit from its global presence, compelling product portfolio and focus on over-the-counter clearing services and optimistic growth projections.
CME Group (CME) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CME (CME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Traders see the odds of a Fed rate cut by September at 100%
The probabilities are based on trading in CME Fed Funds futures contracts.
3 Crypto-Powered Stocks Ready to Explode This Summer
The rise in popularity of cryptocurrencies has been a boon for crypto-powered stocks. In recent months we've witnessed a surge in Bitcoin ( BTC-USD ) prices, climbing an impressive 91% from a year ago.
The 3 Best Financial Services Stocks to Buy in July 2024
While bank stocks are constantly in the headlines, financial services stocks often fly under the radar. Yet, the best financial services stocks enjoy better economics as service providers to the financial system.
CME Group Vs. FMX: May The Race To The Bottom Begin
CME Group Inc. is a leading financial services company with a focus on interest rate and Treasury futures, which have shown strong growth over the years. BGC Group's FMX Futures Exchange aims to challenge CME's monopoly in U.S. interest rate futures trading. In this update, I discuss the main risks and explain why I strongly doubt that FMX can develop into a significant competitor for CME Group.
